Compare · MCK vs SCNX
MCK vs SCNX
Side-by-side comparison of McKesson Corporation (MCK) and Scienture Holdings Inc. (SCNX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MCK and SCNX operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- MCK is the larger of the two at $101.14B, about 6012.6x SCNX ($16.8M).
- Over the past year, MCK is up 18.5% and SCNX is down 81.1% - MCK leads by 99.7 points.
- MCK has been more active in the news (4 items in the past 4 weeks vs 1 for SCNX).
- MCK has more recent analyst coverage (25 ratings vs 0 for SCNX).
- Company
- McKesson Corporation
- Scienture Holdings Inc.
- Price
- $841.44-0.01%
- $0.40-2.90%
- Market cap
- $101.14B
- $16.8M
- 1M return
- +7.11%
- +4.72%
- 1Y return
- +18.53%
- -81.14%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 1
- Recent ratings
- 25
- 0
McKesson Corporation
McKesson Corporation provides healthcare supply chain management, retail pharmacy, community oncology and specialty care, and healthcare information solutions in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment offers CoverMyMeds solution to help patients get the medications; RelayHealth, a workflow solution; RxCrossroads solution for therapies and interventions to biopharma manufacturers; and McKesson Prescription Automation, a customized pharmacy automation technology; and Multi-Client Central Fill as a Service, a pharmacy. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Latest MCK
- Chief Executive Officer Tyler Brian S. sold $6,715,898 worth of shares (8,463 units at $793.56) as part of a pre-agreed trading plan, decreasing direct ownership by 59% to 5,919 units (SEC Form 4)
- McKesson Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form DEFA14A filed by McKesson Corporation
- McKesson Corporation Announces First Quarter Fiscal 2027 Earnings Release Date
- Chief Executive Officer Tyler Brian S. sold $6,559,925 worth of shares (8,463 units at $775.13) as part of a pre-agreed trading plan, decreasing direct ownership by 37% to 14,382 units (SEC Form 4)
- SEC Form DEFA14A filed by McKesson Corporation
- SEC Form DEF 14A filed by McKesson Corporation
- McKesson Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Chief Executive Officer Tyler Brian S. sold $3,760,827 worth of shares (4,929 units at $763.00) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 22,845 units (SEC Form 4)
- SVP, Controller & CAO Rutledge Napoleon B Jr sold $101,612 worth of shares (133 units at $764.00) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 632 units (SEC Form 4)
Latest SCNX
- SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
- SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
- SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team
- SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC
- SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
- Scienture Holdings Inc. filed SEC Form 8-K: Leadership Update
- Scienture Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
- SEC Form 10-Q filed by Scienture Holdings Inc.
- Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline